



I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 8th day of January 2004

By

(Signature of person mailing)

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Mohamed M. Ali Awad, et al.

Examiner: Unknown

APPLICATION NO.: 10/688,566

FILING DATE: October 17, 2003

: Group Art Unit: Unknown

TITLE: Quinoline Derivatives as CRTH2 Antagonists

Mail Stop Patent Applications

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

No fee should be required for this request. If, however, the Commissioner determines that any fee is due please charge it to Deposit Account No. 16-1445. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to deposit Account No. 16-1445. Two copies of this sheet are enclosed.

A prompt and favorable response is earnestly solicited.

Date:

January 8, 2004

Respectfully submitted,

Robert T. Ronau

Robert T. Ronau
Attorney for Applicant(s)
Reg. No. 36,257

Pfizer Inc.
Patent Department, Box 8260-1611
Eastern Point Road
Groton, CT 06340
(860) 441-5910



I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 8th day of January 2004

By

(Signature of person mailing)

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Mohamed M. Ali Awad, et al.

Examiner: Unknown

APPLICATION NO.: 10/688,566

FILING DATE: October 17, 2003

: Group Art Unit: Unknown

TITLE: Quinoline Derivatives as CRTH2 Antagonists

Mail Stop Patent Applications

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

No fee should be required for this request. If, however, the Commissioner determines that any fee is due please charge it to Deposit Account No. 16-1445. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to deposit Account No. 16-1445. Two copies of this sheet are enclosed.

A prompt and favorable response is earnestly solicited.


Date:

January 8, 2004

Respectfully submitted,

Robert T. Ronau
Robert T. Ronau
Attorney for Applicant(s)
Reg. No. 36,257

Pfizer Inc.
Patent Department, Box 8260-1611
Eastern Point Road
Groton, CT 06340
(860) 441-5910



INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i> Page 1 of 1	ATTY. DOCKET NO. PC25227A	SERIAL NO. 10/688,566
	APPLICANT Mohamed M. Ali Awad, et al.	
	FILING DATE October 17, 2003	GROUP Unknown

U.S. PATENT DOCUMENTS												
EXAMINER INITIAL	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS												
DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)												
			XP 002244840, Zhurnal Obschchei Khimii, 1963, 33(6), p. 1956-1958									
			XP 002244841, MCL Screening Compounds, May 24, 2001, Accession #2001:10000970 CHEMCATS									
			XP 002244842, Scientific Exchange Product Line, Accession # 2003:294034 CHEMCATS, Jan 2003									
			XP 002244843, Enamine Product Listing, Accession #2000:1095101 CHEMCATS, Nov 15, 2001									
			XP 002244839, 1966, no. 4, p. 5-16, Trudy Problemnio Laboratoirii Khimii Vysokomolekulyamykh Soedinenii									
			XP 002244845, Vitas-M Screening Collection, Accession #2002:304333 CHEMCATS, Mar. 22, 2001									
			XP 002244844, MicroChemistry Screening Collection, Accession #2001:2763118 CHEMCATS, Oct 3									
			XP 002244846, ChemBridge Product List, Accession #2002:601263 CHEMCATS, Jan 17, 2002									
			XP 002244847, Interchim Intermediates, Accession # 2002:2633209 CHEMCATS, July 9									

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	